name | Reslizumab |
classification | Biologic; anti-interleukin-5 monoclonal antibody |
pharmacokinetics | Reslizumab is administered intravenously. Peak serum concentrations are typically observed within a few hours. The elimination half-life is approximately 20-30 days, resulting in prolonged therapeutic effects after a single dose. Significant hepatic metabolism isn't a major factor; however, renal function can influence the clearance rate. |
suggested dosage | The recommended dosage for Reslizumab in severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwnp) is based on a weight-based titration regimen and is individualized by healthcare providers. Specific dosage information, including weight-adjusted regimens, should be obtained from the prescribing information. It's crucial to discuss appropriate dosages with a healthcare professional, as they will take into account individual patient characteristics. |
indications | Reslizumab is indicated for the treatment of severe eosinophilic asthma in adults and adolescents (12 years and older) who have persistent symptoms despite high-dosage inhaled corticosteroids (ICS) and other controller medicines. It is also indicated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwnp). |
safety in pregnancy | Limited data exists regarding the safety of reslizumab in pregnancy. The potential risks and benefits should be thoroughly discussed with the prescribing physician, considering the severity of the condition and available alternatives. No clear guidelines for use during pregnancy are available, and pregnant patients need careful evaluation. |
safety in breastfeeding | There is insufficient data to determine the safety of reslizumab in breastfeeding mothers. Reslizumab may pass into breast milk; therefore, potential risks and benefits for both the mother and the infant must be evaluated and discussed with a healthcare professional. Breastfeeding should be evaluated as a potential risk-benefit choice. |
side effects | 1 | Injection site reactions (pain, redness, swelling) | 2 | Nasopharyngitis | 3 | Upper respiratory tract infection | 4 | Headache | 5 | Injection site reactions | 6 | Injection-site pain, redness, and swelling | 7 | Influenza | 8 | Nausea | 9 | Diarrhea | 10 | Myalgia | 11 | Arthralgia | 12 | Fatigue | 13 | Cough | 14 | Abdominal pain | 15 | Pharyngolaryngeal pain | 16 | Increased risk of infections (e.g., cellulitis, sinusitis, upper respiratory tract infections) | 17 | Rarely: serious allergic reactions (anaphylaxis), hypersensitivity reactions, and severe skin reactions | 18 | Very rare: liver problems, kidney problems, and neurological issues |
|
alternatives | |
contraindications | Reslizumab is contraindicated in patients with a known hypersensitivity to the drug or any of its components. Existing active infections of severe nature could potentially pose a risk, and the assessment of those risks and benefits needs to be individualized by the physician. |
interactions | No significant drug interactions are known at present. But, drug-drug interactions are not completely understood, and healthcare providers should carefully consider any concurrent medications when prescribing Reslizumab. |
warnings and precautions | 1 | Monitor for allergic reactions during and after infusions. | 2 | Close monitoring of renal and hepatic functions is crucial. | 3 | Patients with a history of severe infections, should be carefully evaluated. | 4 | Infusion-related reactions can occur. | 5 | Regular monitoring for infections is important. |
|
additional informations | Reslizumab is an expensive treatment and may not be suitable for all patients. A thorough assessment of the patient's condition and needs is required before prescribing. |
patient profile | |